Ann Knoop

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

Retrospective Analysis of Topoisomerase IIa Amplifications and Deletions As Predictive Markers in Primary Breast Cancer Patients Randomly Assigned to Cyclophosphamide, Methotrexate, and Fluorouracil or Cyclophosphamide, Epirubicin, and Fluorouracil: Danish Breast Cancer Cooperative Group

Ann Knoop, Helle Knudsen, Eva Balslev et al. · Journal of Clinical Oncology · 2005 · 323 citations · Full text

Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study

Xavier Pivot, Joseph Gligorov, Volkmar Müller et al. · The Lancet Oncology · 2013 · 220 citations

Breast Oncology, Oncology, Intravenous Administration +4

<i>PIK3CA</i> Mutations May Be Discordant between Primary and Corresponding Metastatic Disease in Breast Cancer

Jeanette Dupont Jensen, Anne‐Vibeke Lænkholm, Ann Knoop et al. · Clinical Cancer Research · 2010 · 214 citations

Novel circulating microRNA signature as a potential non‐invasive multi‐marker test in ER‐positive early‐stage breast cancer: A case control study

Annette Raskov Kodahl, Maria Lyng, Harald Binder et al. · Molecular Oncology · 2014 · 185 citations · Full text